Hepatitis B Treatment Market , 2012-2023

January 2018 | 224 pages | ID: H68C81C14F5EN
Precision Business Insights (PBI)

Abstracts

Hepatitis B Treatment Market

Hepatitis-B is also known serum hepatitis which is an infectious disease of the liver caused by Hepatitis-B virus (HBV). Hepatitis B is classified into two types namely, acute and chronic. In this condition, the virus interferes with the hepatocytes and the liver became inflamed. Hepatitis-B is commonly caused through parenteral contacts such as blood, body fluids, and sexual intercourse. Hepatitis-B virus is unable to cross the skin or mucous membrane. People with Lymph proliferative disease, Acquired Immuno Deficiency Syndrome (AIDS), and people treated with immunosuppressant drugs and haemodialysis patients are easily develop an infection with Hepatitis-B Virus. The symptoms of the Hepatitis B do not develop until after a few weeks of exposure. The severity in Hepatitis may cause the cirrhosis, liver failure, and hepatocellular carcinoma (HCC). A vaccine is commonly administered to protect people from the infection. Hepatitis B can be prevented by administering the hepatitis B vaccine to newborn babies, avoiding promiscuity and not having multiple sexual partners, and avoiding sharing of injections and razors can also prevent the Hepatitis B infection.

The global Hepatitis B treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis B infection. According to the World Health Organization (WHO), chronic hepatitis B virus infection occurs in majority of the infants. Rising awareness regarding hepatitis B treatment, increase in the healthcare expenditure, rise in the funding in research and development activities for hepatitis B treatment, and various pipeline products for Hepatitis B treatment might fuel the global hepatitis B treatment market over the forecast period. However, high cost of the hepatitis B treatment and medications, less effectiveness of antiviral drugs against hepatitis B infection might hamper the growth of global hepatitis B treatment market over the forecast period.

Hepatitis B treatment market segmented on the basis of drug class, route 0f administration, and distribution channel

Based on drug class, hepatitis B treatment market has been segmented into the following:

• Chemo Therapy
• Immunosuppressant Therapy
• Nucleoside Analogue

Based on route of administration, hepatitis B treatment market has been segmented into the following:

• Oral
• Parenteral
• Others

Based on distribution channel, hepatitis B treatment market has been segmented into the following:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Geographically, hepatitis B treatment market is in growing stage, as various government organizations are initiating awareness programs to prevent the hepatitis B infection. Increase in the prevalence of hepatitis B infection and liver cirrhosis might fuel the hepatitis B treatment market. According to the World Health Organization, there are currently 240 million chronic carriers of hepatitis B virus in which approximately 15–25% of carriers will develop cirrhosis, hepatocellular carcinoma (HCC), or liver decompensation, and 780,000 will die each year as a result of their infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their share in global hepatitis b treatment market. For instance, in September 2013, Roche and Inovio Pharmaceuticals collaborated on research, development, and commercialization of Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting hepatitis B and prostate cancer. Similarly, in July 2015, Benitec Biopharma and Biomics Biotechnologies are announced that Benitec has acquired the full rights to the pre-clinical ddRNAi-based hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies. In addition, in October 2010, U.S. Food and Drug Administration approved the Baraclude (Entecavir) for hepatitis B treatment with the decompensated liver disease in adults manufactured by Bristol Myers Squibb. Moreover, various drugs for the hepatitis B treatment in the pipeline also expected to propel the hepatitis B treatment market over the forecast period.

Geographically, the hepatitis B treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to hold a dominant share in hepatitis B market owing to increase In the prevalence of hepatitis B infection (according to Centres for Disease Prevention and Control (CDC), approximately 1.4 Million patients in the United States are chronically infected with hepatitis B Virus), rise in the awareness towards the use of noveltechnologies and products for hepatitis B treatment, and increase in the research and development activities are the key factors bolster the hepatitis B treatment market in North America region. Europe holds a key share in hepatitis B treatment market owing to increase in the prevalence of hepatitis B infection (in Russia, the prevalence rate is approximately 3712 cases per 100,000 people), rise in the geriatric population, change in the lifestyle, and increase in the research and development activities might boost the hepatitis B treatment market in Europe region. Asian Pacific is a key region for hepatitis b treatment market attributed to increase in the prevalence of hepatitis B infection (in China, there are 7420 prevalent cases per 100,000 people), rise in the population in Asia Pacific region, and increase in the healthcare infrastructure and healthcare expenditure. Middle East & Africa region expected to exhibit significant growth due to highest prevalence of global hepatitis B infection which is approximately 10,000 prevalent cases per 100,000 people.

Some of the players in hepatitis B treatment market are F. Hoffmann- La Roche Ltd. (Switzerland), GlaxoSmithKline, plc. (U.K.), Bristol-Myers Squibb (U.S), Novartis AG (Switzerland), Merck and Co (U.S), Novira Therapeutics Inc. (U.S.), Johnson & Johnson (U.S.), Inovio Pharmaceuticals Inc. (U.S.), Benitec biopharma Ltd. (Australia), Gilead Sciences (U.S.), Cipla Inc. (India), and Biomics biotechnologies (China) to name a few.

In January 2017, Gilead Sciences, Inc announced that the European Commission granted marketing authorization for Vemlidy (tenofovir alafenamide, TAF) for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg)

In December 2016, Cipla received an approval from American health regulator to market Entecavir tablets used in the treatment of HBV infection

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL HEPATITIS B TREATMENT MARKET INTRODUCTION

2.1. Global Hepatitis B Treatment Market – Taxonomy
2.2. Global Hepatitis B Treatment Market –Definitions
  2.2.1. Drug Class
  2.2.2. Distribution Channel

3. GLOBAL HEPATITIS B TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hepatitis B Treatment Market Dynamic Factors - Impact Analysis

4. GLOBAL HEPATITIS B TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis

5. GLOBAL HEPATITIS B TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

5.1. Chemo Therapy
  5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Immunosuppressant Therapy
  5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis

6. GLOBAL HEPATITIS B TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

6.1. Oral
  6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Parenteral
  6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Others
  6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL HEPATITIS B TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL HEPATITIS B TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

8.1. North America
  8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Hepatitis B Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA HEPATITIS B TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

9.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Chemo Therapy
  9.1.2. Immunosuppressant Therapy
  9.1.3. Nucleoside Analogue
9.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.2.1. Oral
  9.2.2. Pareneteal
  9.2.3. Others
9.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.3.1. Hospital Pharmacies
  9.3.2. Retail pharmacies
  9.3.3. Online Pharmacies
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Hepatitis B Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
9.6. North America Hepatitis B Treatment Market Dynamics – Trends

10. EUROPE HEPATITIS B TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

10.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Chemo Therapy
  10.1.2. Immunosuppressant Therapy
  10.1.3. Nucleoside Analogue
10.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.2.1. Oral
  10.2.2. Pareneteal
  10.2.3. Others
10.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.3.1. Hospital Pharmacies
  10.3.2. Retail pharmacies
  10.3.3. Online Pharmacies
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Hepatitis B Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.6. Europe Hepatitis B Treatment Market Dynamics – Trends

11. ASIA-PACIFIC HEPATITIS B TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

11.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Chemo Therapy
  11.1.2. Immunosuppressant Therapy
  11.1.3. Nucleoside Analogue
11.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.2.1. Oral
  11.2.2. Pareneteal
  11.2.3. Others
11.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.3.1. Hospital Pharmacies
  11.3.2. Retail pharmacies
  11.3.3. Online Pharmacies
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Hepatitis B Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.6. Asia-Pacific Hepatitis B Treatment Market Dynamics – Trends

12. LATIN AMERICA HEPATITIS B TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

12.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Chemo Therapy
  12.1.2. Immunosuppressant Therapy
  12.1.3. Nucleoside Analogue
12.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.2.1. Oral
  12.2.2. Pareneteal
  12.2.3. Others
12.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Hospital Pharmacies
  12.3.2. Retail pharmacies
  12.3.3. Online Pharmacies
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Hepatitis B Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Hepatitis B Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA HEPATITIS B TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

13.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Chemo Therapy
  13.1.2. Immunosuppressant Therapy
  13.1.3. Nucleoside Analogue
13.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.2.1. Oral
  13.2.2. Pareneteal
  13.2.3. Others
13.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.3.1. Hospital Pharmacies
  13.3.2. Retail pharmacies
  13.3.3. Online Pharmacies
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Gulf Cooperation Council (GCC) Countries
  13.4.2. Israel
  13.4.3. South Africa
  13.4.4. Rest of MEA
13.5. MEA Hepatitis B Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.6. MEA Hepatitis B Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. F. Hoffmann- La Roche Ltd. (Switzerland)
  14.2.2. GlaxoSmithKline, plc. (U.K.)
  14.2.3. Bristol-Myers Squibb (U.S)
  14.2.4. Novartis AG (Switzerland)
  14.2.5. Merck and Co Inc., (U.S)
  14.2.6. Novira Therapeutics Inc. (U.S.)
  14.2.7. Johnson & Johnson Services Inc., (U.S.)
  14.2.8. Inovio Pharmaceuticals Inc. (U.S.)
  14.2.9. Benitec biopharma Ltd. (Australia)
  14.2.10. Gilead Sciences (U.S.)
  14.2.11. Cipla Inc. (India)
  14.2.12. Biomics biotechnologies (China)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS